ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 546
Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 534
Antibodies to Malondialdehyde-Acetaldehyde Adducts Are Highly Expressed in Rheumatoid Arthritis Synovial Fluid 
9:00AM-11:00AM
Abstract Number: 518
Antibody Responses to Citrullinated Porphyromonas Gingivalis Peptidylarginine Deiminase: Associations with Disease Risk Factors and Severity in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 520
Antibody to Porphyromonas Gingivalis in Pre-Clinical Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 525
Association Between Fine Specificity of Anti-Citrullinated Peptide Antibodies and High Resolution Computed Tomography Parenchymal Lung Changes in Patients with Early RA
9:00AM-11:00AM
Abstract Number: 545
Baseline Serum Soluble Interleukin–2 Receptor Alpha (sIL–2Rα) Levels Increased as Intervals Decreased from Cohort Entry to Onset of Incident Rheumatoid Arthritis (pre–RA), not Observed in Matched Control (CN) Subjects
9:00AM-11:00AM
Abstract Number: 527
Characterisation of the Antibody Response to a Citrullinated Peptide – Derived from the Porphyromonas Gingivalis Peptidyl Arginine Deiminase Enzyme – in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 526
Citrullinated Fibrinogen Promotes Bone Marrow Mesenchymal Stem Cells to Assume a Proinflammatory Phenotype
9:00AM-11:00AM
Abstract Number: 540
Clinical Relevance of Etanercept Levels and Anti-Etanercept Antibodies in Long-Term Treatment of Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 523
Elevated Antibody Response to Porphyromonas Gingivalis Detected in Sera Years before the Clinical Onset of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 544
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
9:00AM-11:00AM
Abstract Number: 531
Immune Responses to Mycobacterium Heat Shock Protein 70 Accompany Self-Reactivity to Human Bip in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 529
Immunoglobulin-a and Immunoglobulin-G Isotypes of Anti-CCP Antibodies Are Present in the Sputum of Subjects at Risk for Future Development of RA
9:00AM-11:00AM
Abstract Number: 530
Immunomodulation of Naïve RA Patients PBMCs with a Multi-Epitope Peptide Derived from Citrullinated Autoantigens
9:00AM-11:00AM
Abstract Number: 519
In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage
9:00AM-11:00AM
Abstract Number: 536
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By TNF-Alpha and IL-6 Axis in Accompany with Disease Activity in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 541
Microrna-125b Expression in PBMCs Is Associated with Disease Activity in Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 538
Multidrug Resistant Lymphocytes of Patients with Rheumatoid Arthritis Are Predictive for DMARD and Glucocorticoid Treatment Response
9:00AM-11:00AM
Abstract Number: 524
Plasma Concentrations of Antibodies to Porphyromonas Gingivalis Are Increased before Onset of Symptom of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 532
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression: Preliminary Results
9:00AM-11:00AM
Abstract Number: 539
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
9:00AM-11:00AM
Abstract Number: 528
RA33 Challenges the Paradigm of Autoantigen Selection in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 542
Reduced Expression of Mir-204 in Early RA Promotes Inflammatory Pathways in Synovial Fibroblasts
9:00AM-11:00AM
Abstract Number: 521
Targeted Quantitative Analysis to Identify Citrullinated Peptides in the Synovial Fluid of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 535
Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 537
The Course of Bone Marrow Edema in Early Undifferentiated and Rheumatoid Arthritis; A Longitudinal MRI Study on Bone Level
9:00AM-11:00AM
Abstract Number: 522
The Expression of mRNA for Peptidylarginine Deiminase Type 2 and Type 4 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 543
The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Autoantibody Positivity and Radiographic Progression
9:00AM-11:00AM
Abstract Number: 533
The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology